scholarly journals Management of balance and gait in older individuals with Parkinson’s disease

Aging Health ◽  
2011 ◽  
Vol 7 (2) ◽  
pp. 205-218
Author(s):  
Ryan P Duncan ◽  
Abigail L Leddy ◽  
Gammon M Earhart
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Older Individuals

scholarly journals Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease

2020 ◽  
Vol 10 (5) ◽  
pp. 284 ◽  
Author(s):  
Casey A. Hribar ◽  
Peter H. Cobbold ◽  
Frank C. Church
Keyword(s):  
Older Adults ◽  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Vitamin D3 ◽  
The Elderly ◽  
Vitamin D Supplementation ◽  
Older Individuals ◽  
Related Quality ◽  
Cholecalciferol Supplementation

While we are still learning more about COVID-19, caused by the novel SARS-CoV-2 virus, finding alternative and already available methods to reduce the risk and severity of the disease is paramount. One such option is vitamin D, in the form of vitamin D3 (cholecalciferol) supplementation, due to its potential antiviral properties. It has become apparent that older individuals have a greater risk of developing severe COVID-19, and compared to younger adults, the elderly have lower levels of vitamin D due to a variety of biological and behavioral factors. Older adults are also more likely to be diagnosed with Parkinson’s disease (PD), with advanced age being the single greatest risk factor. In addition to its immune-system-modulating effects, it has been suggested that vitamin D supplementation plays a role in slowing PD progression and improving PD-related quality of life. We completed a review of the literature to determine the relationship between vitamin D, PD, and COVID-19. We concluded that the daily supplementation of 2000–5000 IU/day of vitamin D3 in older adults with PD has the potential to slow the progression of PD while also potentially offering additional protection against COVID-19.

Comparison of Pedometer and Accelerometer Derived Steps in Older Individuals With Parkinson’s Disease or Osteoporosis Under Free-Living Conditions

2014 ◽  
Vol 22 (4) ◽  
pp. 550-556 ◽  
Author(s):  
Martin Benka Wallén ◽  
Ing-Mari Dohrn ◽  
Agneta Ståhle ◽  
Erika Franzén ◽  
Maria Hagströmer
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Living Conditions ◽  
Older Individuals ◽  
Limits Of Agreement ◽  
Free Living ◽  
Clinical Evaluations ◽  
Recorded Data ◽  
Free Living Conditions

Aim:To compare self-reported pedometer steps with accelerometer steps under free-living conditions in individuals with Parkinson’s disease (PD) or osteoporosis (OP).Methods:Seventy-three individuals with PD and 71 individuals with OP wore a pedometer (Yamax LS2000) and an accelerometer (ActiGraph GT1M/GT3X+) simultaneously for one week.Results:Fifty-one individuals with PD (72.6 ± 5.3 years) and 61 with OP (75.6 ± 5.3 years) provided simultaneously recorded data for 3–7 consecutive days. Pedometer steps were significantly lower than accelerometer steps in the PD group (p = .002) but not in the OP group (p = .956). Bland-Altman plots demonstrated wide limits of agreement between the instruments in both PD (range = 6,911 steps) and OP (range = 6,794 steps).Conclusion:These results suggest that the ActiGraph GT1M/GT3X+ should be preferred over the Yamax LS2000 for the assessment of steps in both research and clinical evaluations, particularly in individuals with PD or altered gait.

scholarly journals Polypharmacy and Hyperpolypharmacy in Older Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Gerontology ◽  
2022 ◽  
pp. 1-10
Author(s):  
Akshaya Srikanth Bhagavathula ◽  
Wubshet Tesfaye ◽  
Kota Vidyasagar ◽  
Daniela Fialova
Keyword(s):  
Older Adults ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Observational Studies ◽  
Meta Analysis ◽  
Adverse Outcomes ◽  
Older Individuals ◽  
Drug Related Problems ◽  
Inclusion Criteria ◽  
Pooled Prevalence

<b><i>Background and Aim:</i></b> Polypharmacy (concomitant use of 5–9 medicines) and hyperpolypharmacy (concomitant use of over 10 medicines) were observed to be more frequent in older adults (≥65 years) and associated with adverse outcomes. Their prevalence and risk in older patients with Parkinson’s disease (PD) remain unknown. We aimed to synthesize the extant evidence on the prevalence and risk of polypharmacy and hyperpolypharmacy in older adults with PD. <b><i>Methods:</i></b> A systematic literature search was performed in PubMed/MEDLINE, Scopus, and Embase databases to identify pertinent studies published from 2000 to July 2021. Observational studies reporting the prevalence and association with disease of polypharmacy/hyperpolypharmacy in older adults with PD were meta-analyzed. Pooled prevalence and odds ratio (OR) with 95% confidence intervals (CIs) were calculated. <b><i>Results:</i></b> Out of the total 499 studies identified, 6 fulfilled the inclusion criteria and comprised 7,171 participants. The overall prevalence of polypharmacy and hyperpolypharmacy was 40% (95% CI: 37–44) and 18% (95% CI: 13–23), respectively. A meta-analysis of 4 studies indicated a significant association between polypharmacy (OR: 1.94, 95% CI: 1.26–2.62; <i>p</i> &#x3c; 0.001) and PD. Hyperpolypharmacy was also strongly associated with PD (OR: 3.11, 95% CI: 2.08–4.14; <i>p</i> &#x3c; 0.001). <b><i>Conclusion:</i></b> Polypharmacy (40%) and hyperpolypharmacy (18%) are highly prevalent and eventually increase the risk of drug-related problems in older adults with PD. Therefore, interventions that ensure rational geriatric pharmacotherapy are of critical importance for the older population with neurogenerative disorders.

scholarly journals PARKINSON’S DISEASE

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S574-S574
Author(s):  
Madeleine Hackney
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Resistance Training ◽  
Muscle Power ◽  
Whole Body ◽  
Type I ◽  
Older Individuals ◽  
Movement Initiation ◽  
Exercise Interventions ◽  
Disease Specific

Abstract The risk of Parkinson’s Disease (PD) increases with age as over 90% of individuals are diagnosed after the age of 50. Older individuals with PD face a compounding burden of reduced muscle power, decreased muscular endurance, and weakness related to disease specific processes such as an altered pattern of motor unit activation, rigidity and bradykinesia. Individuals with PD demonstrate a tendency towards type I fiber hypertrophy, and a greater heterogeneity for type II fibers. Despite the disease specific burden of PD, exercise results in improved mobility, balance, and movement initiation. Interventions like resistance training have resulted in strength gains, and other interventions, such as tango dancing may be particularly useful for balance improvements, as the movement involves multi-directional perturbations and whole-body coordination. Here, we will discuss the use of novel exercise interventions, such as resistance training and tango, to improve the muscle and mobility function of older adults with PD.

scholarly journals Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages

2017 ◽  
Vol 75 (8) ◽  
pp. 497-502 ◽  
Author(s):  
Raissa Carla Moreira ◽  
Marise Bueno Zonta ◽  
Ana Paula Serra de Araújo ◽  
Vera Lúcia Israel ◽  
Hélio A. G. Teive
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Daily Living ◽  
Rating Scale ◽  
Older Individuals ◽  
Daily Living Activities ◽  
Disease Rating ◽  
Progression Markers

ABSTRACT Objective To investigate which factors are associated with the quality of life decline in Parkinson’s disease patients from mild to moderate stages. Methods The Unified Parkinson’s Disease Rating Scale and Parkinson’s Disease Questionnaire-39 were used to evaluate clinical/functional data and the quality of life. Results The markers of clinical/functional worsening were drooling (p < 0.004), need for assistance with hygiene (p = 0.02), greater freezing frequency (p = 0.042), bradykinesia (p = 0.031), greater intensity of the resting tremor (p = 0.035) and “pill rolling” (p = 0.001). The decline in quality of life was related to stigma (p = 0.043), greater impairment in cognition (p = 0.002), mobility (p = 0.013) and for daily living activities (p = 0.05), and was considered more significant in men, married, older individuals, and those with a longer time of disease. Conclusions The quality of life worsening markers at the moderate stage were related to stigma, worsening of cognition, and to greater impairment in mobility and daily living activities.

scholarly journals Association between Sleep, Alzheimer’s, and Parkinson’s Disease

Biology ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1127
Author(s):  
Sumire Matsumoto ◽  
Tomomi Tsunematsu
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Protein Misfolding ◽  
Older Individuals ◽  
Cognitively Normal ◽  
Potential Biomarker ◽  
Increased Risk ◽  
Sleep Abnormalities ◽  
Protein Misfolding And Aggregation ◽  
The Brain

The majority of neurodegenerative diseases are pathologically associated with protein misfolding and aggregation. Alzheimer’s disease (AD) is a type of dementia that slowly affects memory and cognitive function, and is characterized by the aggregation of the β-amyloid protein and tau neurofibrillary tangles in the brain. Parkinson’s disease (PD) is a movement disorder typically resulting in rigidity and tremor, which is pathologically linked to the aggregation of α-synuclein, particularly in dopaminergic neurons in the midbrain. Sleep disorders commonly occur in AD and PD patients, and it can precede the onset of these diseases. For example, cognitively normal older individuals who have highly fragmented sleep had a 1.5-fold increased risk of subsequently developing AD. This suggests that sleep abnormalities may be a potential biomarker of these diseases. In this review, we describe the alterations of sleep in AD and PD, and discuss their potential in the early diagnosis of these diseases. We further discuss whether sleep disturbance could be a target for the treatment of these diseases.

scholarly journals Frequency of Parkinsonism and Parkinson Disease in African Americans in the Chicago Community

2021 ◽  
Author(s):  
Meagan Bailey ◽  
Lisa M Shulman ◽  
Diane Ryan ◽  
Bichun Ouyang ◽  
Joshua M Shulman ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Studies ◽  
Rating Scale ◽  
Community Dwelling ◽  
Self Report ◽  
Older Individuals ◽  
Cognitive Differences ◽  
Disease Rating ◽  
And Gender

Abstract Background There is paucity of data about African American (AA) patients with Parkinson’s disease (PD) and parkinsonism which may precede PD in older adults. Prior studies suggest that there are lower rates of PD in the AA population, with more cognitive impairment in AA with PD. This study aimed to investigate differences in PD, parkinsonism, and cognition between White and AA populations in 3 longitudinal epidemiologic cohort studies of aging. Methods This study examined parkinsonism, PD frequency, and cognition of community-dwelling older individuals in 3 longitudinal epidemiologic cohort studies. Parkinsonism was based on an exam utilizing the modified Unified Parkinson’s Disease Rating Scale performed by a nurse. PD was based on self-report, medications used for treatment of PD, and examination findings. Cognition was assessed using 19 performance-based tests that assess 5 cognitive domains. Results AA participants were less likely to have parkinsonism compared to Whites, even with age and gender differences. Frequency of PD was not significant between groups. AA were more likely to have lower cognitive scores as compared to Whites. AA were less likely to have parkinsonism even with controlling for cognitive differences between groups. Conclusions Parkinsonian signs are present among AA in the community at lower rates than in White individuals. Cognitive profiles of AA and Whites with parkinsonism may be different, suggesting differing contributions of pathology to cognitive decline and parkinsonism between groups. Additional research is needed to understand the progression of parkinsonism to PD, as well as to understanding the cognitive differences in AA with parkinsonism.

Alterations of Brain Signal Oscillations in Older Individuals with HIV Infection and Parkinson’s Disease

2020 ◽  
Author(s):  
Eva M. Müller-Oehring ◽  
Jui-Yang Hong ◽  
Rachel L. Hughes ◽  
Dongjin Kwon ◽  
Helen M. Brontë-Stewart ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Hiv Infection ◽  
Older Individuals
Sign in / Sign up

Export Citation Format

Share Document